Ivermectin: FDA-Approved Indications, Dosing, and Contraindications
Ivermectin is FDA-approved for two parasitic infections in humans: strongyloidiasis and onchocerciasis, with specific weight-based dosing regimens and a critical contraindication in children weighing less than 15 kg. 1
FDA-Approved Indications
Strongyloidiasis (Intestinal Threadworm)
- Dosing: Single oral dose of 200 mcg/kg body weight 1
- Taken on an empty stomach with water
- Additional doses generally not necessary, but follow-up stool examinations required to verify eradication
- Use concentration techniques (Baermann apparatus) for stool examination as larval counts may be very low 1
Dosing by weight:
- 15-24 kg: 1 tablet (3 mg)
- 25-35 kg: 2 tablets
- 36-50 kg: 3 tablets
- 51-65 kg: 4 tablets
- 66-79 kg: 5 tablets
- ≥80 kg: 200 mcg/kg 1
Onchocerciasis (River Blindness)
- Dosing: Single oral dose of 150 mcg/kg body weight 1
- Taken on an empty stomach with water
- In mass distribution campaigns, most common dosing interval is 12 months
- For individual patients, retreatment may be considered at intervals as short as 3 months 1
Dosing by weight:
- 15-25 kg: 1 tablet (3 mg)
- 26-44 kg: 2 tablets
- 45-64 kg: 3 tablets
- 65-84 kg: 4 tablets
- ≥85 kg: 150 mcg/kg 1
Additional FDA-Approved Uses (Topical Formulation)
- Rosacea (inflammatory lesions in adults): topical cream formulation 2
- Head lice, scabies: oral and topical formulations 3, 2
Critical Contraindications and Safety Considerations
Primary Contraindication
Children weighing less than 15 kg: Current FDA labeling contraindicates use in this population 1, though emerging evidence suggests safety may be acceptable 4. Until regulatory approval changes, this remains an absolute contraindication in clinical practice.
Loiasis Co-infection (Critical Safety Concern)
Hypermicrofilaremia with Loa loa (>8,000 mf/mL): Ivermectin is contraindicated or requires extreme caution due to risk of severe adverse events including encephalitis 5
Microfilarial thresholds for safe ivermectin use in loiasis:
- Most guidelines recommend use only when microfilarial load is <8,000 mf/mL 5
- Some sources suggest safety up to 30,000 mf/mL, but this is controversial 5
- Above 50,000 mf/mL: elevated risk for severe Mazzotti reaction 5
Alternative treatment in loiasis with high microfilarial loads:
- Use albendazole instead (400-800 mg daily for 10-28 days) 5
- Consider apheresis as adjunct for loads >8,000 mf/mL 5
Pregnancy and Lactation
- Not specifically addressed in provided FDA labeling, but use caution and evaluate risk-benefit ratio
Drug Interactions
- CYP3A4 substrates: Ivermectin is primarily metabolized by CYP3A4 1
- High-fat meals increase bioavailability approximately 2.5-fold 1
Mechanism and Safety Profile
Ivermectin binds selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing paralysis and death of parasites 1. Its safety in mammals is attributed to:
- Low affinity for mammalian ligand-gated chloride channels
- Does not readily cross the blood-brain barrier in humans 1
- Over 25 years of clinical use demonstrates excellent safety profile 2
Adverse events: Generally mild and self-limiting, occurring in approximately 1.4% of treated children in systematic review 4. High-dose studies (up to 10 times FDA-approved doses) showed no CNS toxicity 6.
Important Clinical Pitfalls
Recrudescence in strongyloidiasis: Larvae may reappear up to 106 days post-treatment; perform at least three stool examinations over three months to ensure eradication 1
Anterior chamber microfilariae increase: Transient increase in eye microfilariae at day 3 post-treatment for onchocerciasis, but significant decreases occur by 3-6 months 1
Scabies treatment failure: Single-dose regimen shows only 58% success rate versus 98% with two doses one week apart; always prescribe the two-dose regimen 7
Food effects: Administer on empty stomach unless specifically using food to enhance absorption for certain indications 1
Non-FDA Approved Uses (Not Recommended)
COVID-19: Multiple meta-analyses demonstrate ivermectin does not reduce mortality, hospitalization, or improve clinical outcomes in COVID-19 patients 8, 9. It should not be used for this indication despite ongoing controversy.